Formation Bio
-78%
est. 2Y upside i
Formation Bio (FKA TrialSpark) is a tech-driven pharma company changing the way drug development is done.
Rank
#3561
Sector
Biotechnology, AI-driven Drug Development
Est. Liquidity
~2Y
Data Quality
Data: LowGiven an entry valuation of $1.8B based on a stale round, high preference overhang ($615M), and uncertain growth, the expected equity upside over 2 years is -78%.
Last updated: July 21, 2026
If IPO window opens and category leadership allows multiple to expand to 30x, exit value reaches $1.84B, but dilution reduces upside to -18%.
Multiple converges to 15x, exit value $0.92B, dilution leads to -69% upside.
Multiple compresses to 8x, exit value $0.49B below preference stack, common stock returns -100%.
Preference Stack Risk
severeFunding Intensity
34%Total funding of $615M represents 34.2% of valuation, implying significant preference overhang.
Dilution Risk
highLikely need to raise additional capital within 24 months, potentially diluting existing holders by 15-25%.
Secondary Liquidity
noneNo secondary market activity reported; liquidity expected only through IPO or acquisition.
Other — 24 roles
- Associate Director, Bioanalytical Development · New York, NY; Boston, MA
- Associate Director, Drug Product Development · New York, NY; Boston, MA
- Associate Director, Drug Substance, Biologics · New York, NY; Boston, MA
- +21 more →
Last updated: March 10, 2026
Questions to Ask at the Interview
Strategic questions based on Formation Bio's data — designed to show you've done your homework.
- 1
“How does Formation Bio's platform differentiate from Recursion and Schrodinger's approaches?”
- 2
“What is the company's path to profitability given its high burn rate?”
- 3
“Given the preference stack, what is the realistic common stock outcome if the company is acquired below $615M?”
Community
Valuation Sentiment
Our model estimates -78% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.